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Tumors are often characterized by hypoxia, vascular abnormalities, low extracellular 
pH, increased interstitial fluid pressure, altered choline-phospholipid metabolism, and 
aerobic glycolysis (Warburg effect). The impact of these tumor characteristics has been 
investigated extensively in the context of tumor development, progression, and treat-
ment response, resulting in a number of non-invasive imaging biomarkers. More recent 
evidence suggests that cancer cells undergo metabolic reprograming, beyond aerobic 
glycolysis, in the course of tumor development and progression. The resulting altered 
metabolic content in tumors has the ability to affect cell signaling and block cellular 
differentiation. Additional emerging evidence reveals that the interaction between tumor 
and stroma cells can alter tumor metabolism (leading to metabolic reprograming) as well 
as tumor growth and vascular features. This review will summarize previous and current 
preclinical, non-invasive, multimodal imaging efforts to characterize the tumor microen-
vironment, including its stromal components and understand tumor–stroma interaction 
in cancer development, progression, and treatment response.
Keywords: cancer, microenvironment, stroma, metabolic cooperation, tumor–stroma interaction, preclinical 
multimodal imaging
iNTRODUCTiON—THe TUMOR MiCROeNviRONMeNT (TMe)
The TME (Figure 1A), composed of tumor cells and stroma, is often characterized by hypoxia, vascular 
abnormalities, low extracellular pH (pHe), increased interstitial fluid pressure (1–7), increased aero-
bic glycolysis (Warburg effect) (8, 9), glutamine addiction (10–13), and altered choline-phospholipid 
metabolism (14–19). Recent evidence suggests that metabolic reprograming in the course of tumor 
development and progression increases in more aggressive cancer cells/tumors the ability to easily 
adapt metabolism to the most advantageous pathways, beyond the Warburg effect, in order to ensure 
their growth and survival in response to varying environmental stimuli, such as hypoxia or limited 
nutrient supply (20–24). Altered metabolic content in tumors may affect cell signaling and degree of 
cellular differentiation (11, 25–27).
While previous research focused extensively on the tumor cells, over the last two decades or so, 
further evidence emerged that the tumor stroma is altered during tumor development/progression 
and that the tumor–stroma interaction plays an essential role in tumor metabolism (Figure  2), 
development, progression, and treatment response (2, 22, 23, 26, 28–37).
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FiGURe 2 | Models of cancer cell–cancer-associated fibroblast (CAF) metabolic cooperation in the tumor microenvironment, promoting survival, 
growth, and metastases (38, 39).
FiGURe 1 | The tumor microenvironment (TMe). (A) Components  
and in vivo imaging of the TME. Immune cells include tumor-associated 
macrophages, antigen-presenting cells, myeloid-derived suppressor cells, 
and lymphocytes; CAFs, cancer-associated fibroblasts; MSCs, mesenchymal 
stem cells; ECM, extracellular matrix, consisting of collagens, laminins, and 
other matrix proteins, which is remodeled by ECM-degrading proteases; 
endothelial cells, pericytes, and vascular ECM compose the tumor blood and 
lymph vasculature. (B) Preclinical in vivo imaging of the TME. MRI, magnetic 
resonance imaging; PET, positron emission tomography; SPECT, single 
photon emission computer tomography; CT, computer tomography; US, 
ultrasound.
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The stroma in solid tumors consists of extracellular matrix 
(ECM), and stromal cells, including fibroblasts, endothelial 
cells, pericytes, and various immune cells, such as macrophages, 
neutrophils, mast cells, myeloid progenitors, and lymphocytes 
(Figure 1A), with cancer cells playing an active role in the recruit-
ment and metabolic reprograming of stromal cells (Figure  2) 
(22, 26, 40) and the dynamic remodeling of ECM by tumor and 
stromal cells promoting tumor progression (41–44).
Multiple preclinical imaging techniques (Table 1; Figure 1B) 
have been developed to visualize and quantify specific character-
istics of the TME (5, 45, 46). This review summarizes the efforts 
to image and characterize non-invasively the TME (Figure  1), 
including its stromal components, and tumor–stroma interaction 
(Figures  2–7) in preclinical cancer. Stromal components and 
their imaging are described in the context of preclinical cancer 
in Section “The Tumor Stroma and Its Imaging.” Section “Non-
invasive Multimodal Imaging of Tumor–Stroma Interaction” 
focuses on the more recent attempts to assess the interaction 
of stromal components with cancer cells by non- or minimally 
invasive preclinical multimodal imaging.
THe TUMOR STROMA AND iTS iMAGiNG
In this chapter, we describe briefly the stromal components and 
their imaging with its strengths and limitations.
The eCM
The ECM, a complex structure composed of laminins, collagens, 
proteoglycans, fibronectin, elastin, etc. (71), changes its composi-
tion during cancer progression (41, 72, 73). Many of its compo-
nents are regulated by matrix metalloproteinases (MMPs) which 
are involved in growth signaling [by proteolytic activation of the 
transforming growth factor-β (TGF-β) pathway], apoptosis, and 
angiogenesis (73–76).
Available imaging methods focus on targeting the ECM 
component itself or the enzymes that degrade it, typically, by 
using activatable imaging probes (Figure 1B; Table 1). Imaging 
of cell–matrix adhesion can elucidate the dynamic interplay of 
TABLe 1 | Summary of modalities for in vivo imaging of the tumor microenvironment in preclinical (small animal) tumor models.
imaging modality Resolution Contrast agent
in-plane Coverage/
depths
Temporal 
per frame
Optical Bioluminescence imaging (47, 48) BLI >3–5 μm 1–2 cm >1 s to min Reporter genes
Fluorescence imaging (47, 48) FLI 2–3 µm <1 cm >1 s to min Fluorophores, fluorescent nanoparticles
Fluorescence lifetime microscopy (49) FLIM nm range ~1,000 μm >1 s to min Fluorophores, fluorescent nanoparticles
Fluorescence micro-lymphangiography (50) FML 50 µm 200 µm Video rates FITC-dextran
Fluorescence molecular tomography (51, 52) FMT <1 mm 1–2 mm >1 s to min NIRF dyes, quantum dots, reporter genes
Fourier transform infrared imaging (53–56) FTIR >~3–5 μm <20 μm >1 ms to min Endogenous
Near-infrared fluorescence imaging (50) NIRF ~200 μm <3–4 cm 50–800 ms NIRF dyes, quantum dots, reporter genes
Optical coherence tomography (57) OCT <7.5 μm 2–3 mm <1 s Endogenous
Photoacoustic imaging (tomography) (52, 58–60) PAI (PAT) 100 µm <5–6 cm >1 s to min Fluorophores, nanoparticles, quantum dots
Second-harmonic generation microscopy (61, 62) SHG <1 μm ≤1 mm >10 s Endogenous
Third-harmonic generation microscopy (61) THG <1 μm ≤1 mm >10 s Endogenous
X-rays Computer tomography (47, 48, 50, 52) CT ~50–200 μm Whole body >20 s Water-soluble, iodinated probes
Magnetic 
resonance
Magnetic resonance imaging
(47, 48, 50, 52, 63)
MRI ~25–100 μm Whole body >2 min Label-free
0.1–0.3 mm Whole body min to h Gd- or iron-oxide-based probes; 
dendrimer-based macromolecules
Magnetic resonance spectroscopic imaging (64) MRSI mm range Whole body min to h Endogenous; injected marker or metabolic 
substrates
Electron paramagnetic resonance imaging (65) EPR >0.5 mm cm min to h Injected tracer
Nuclear Positron emission tomography (47, 48, 52) PET 1–2 mm Whole body >10 s to min Radiolabeled substrates (nutrients, 
antibodies, antibody fragments), activatable 
probes
Single photon emission computer tomography 
(47, 52)
SPECT 1–2 mm Whole body min Radiolabeled antibodies, antibody 
fragments, and antigens
Ultrasound Ultrasound imaging (47, 52) US 50–500 µm mm to cm >1 s to min Endogenous; targeted microbubbles
Imaging modalities are color-coded separating optical, X-ray, magnetic resonance-, nuclear-(radioactivity-), and ultrasound-based imaging methods.
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cells and surrounding tissue during ECM remodeling, immune 
cell recruitment, wound healing, and cancer metastasis (77).
Collagen Imaging
Methods, such as colorimetry (78), weight measurements (79), 
atomic force microscopy (80–82), and immunostaining (83–85), 
to image collagen structures risk their destruction and are limited 
by their in  vivo translatability. The dorsal skinfold (window) 
chamber setup allows optical measurements by replacing skin 
with glass but may lead to collagen structural changes due to 
inflammation and mechanotransduction by the glass (86). The 
advances in ultrafast optics significantly improved the ability 
to image fibrillar collagen (the predominant structural protein 
in mammalian ECM and mostly type I) by second-harmonic 
generation (SHG) or third-harmonic generation (61) microscopy 
in vivo and ex vivo (87–91). The strength of SHG imaging is its 
specificity to fibrillar collagen (62, 87, 89, 92) and that it can be 
fairly easily combined with other optical imaging methods, in vivo 
(Figures 3–5A) and ex vivo (49, 90, 93–95). Ability for clinical 
translation has been demonstrated in breast cancer patients by 
combining SHG and bright-field high-resolution microscopy 
with large field of view to design a semi-automated technique 
to predict survival based on collagen fiber classifications (93). 
Recently, confocal microscopy has been used in vivo to detect col-
lagen turnover after introduction of fluorescent fibrillar collagen 
into the dermis of live mice (96). However, all optical imaging 
methods suffer from their limited imaging depth, rendering them 
often an invasive tool and limiting their clinical translation (49, 
57). Thus, the diagnosis and treatment of pathologies related to 
collagen remodeling has benefited greatly from the development 
of collagen-binding or hybridizing peptides, bearing an imag-
ing contrast agent (CA) for, e.g., magnetic resonance imaging 
(MRI) or fluorescence imaging, or theranostic agents, to image 
triple-helical, intact, and/or unfolded, denatured collagen and 
treatment response (97). Other imaging modalities [e.g., ultra-
sound (US) (98, 99), optical coherence tomography (OCT) (100, 
101), Fourier transform infrared spectroscopic imaging (53), or 
multispectral photoacoustic imaging (PAI) (102)], and various 
FiGURe 3 | intravital microscopy of the tumor microenvironment. (A) Epifluorescence microscopy was used to monitor and quantify tumor growth in a human 
fibrosarcoma xenograft model. The invasion of tumor into the surrounding tissue during growth can be visualized (white arrowheads). Bar 50 µm. Adapted with 
permission from Ref. (66). (B) Tumor morphology, vascularization, proliferation, and apoptosis in a human fibrosarcoma xenograft, as detected by intravital 
microscopy: tumor cells express cytoplasmic DsRed2 and nuclear histone 2B (H2B)-EGFP. Collagen fibers are detected by second-harmonic generation. 
Non-disrupted vessels are detected from the fluorescence signal of i.v.-administered Alexa660-Dextran. Bar 50 µm. Nuclear morphology including mitotic (white 
arrowheads) and apoptotic figures (black arrowhead) can be derived and quantified from imaging H2B-EGFP and DsRed2. Insets show prophase (P), metaphase 
(M), late anaphase (LA), and apoptotis (A). Bar 50 µm. Adapted with permission from Ref. (66).
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collagen-targeted agents, e.g., quantum dots (84, 85, 103, 104) 
or collagen-mimetic peptide-based imaging agents (105, 106) 
are being developed/applied to improve collagen imaging and to 
measure collagen turnover during tissue remodeling.
MMP Imaging
The key role that various MMPs play during cancer initiation 
and progression, with clear links to tumor invasion and metas-
tasis (107), make them desirable treatment and cancer imag-
ing targets (108). Targeted probes to image MMPs in  vivo by 
optical imaging (fluorescence and bioluminescence), positron 
emission tomography (PET), single photon emission computer 
tomography (SPECT), and MRI have been developed (108–110), 
with a “broad-spectrum” MMP-activatable fluorescence probe 
available commercially (MMPSense, PerkinElmer, Akron, OH, 
USA). Each modality and imaging probe displays strengths and 
weaknesses in effectively imaging MMP activity (108, 110). 
However, optical imaging has limited penetration depth (108) 
and, while tomography is possible, anatomical information is 
lacking. Targeted, inhibitor-based PET and SPECT probes har-
ness the excellent sensitivity of radioactive tracers and may be 
theranostic, but their synthesis may be difficult and, so far, it 
has not been possible to quantify proteolytic activity in vivo due 
to non-specific binding (108, 109, 111). Recently, an 18F-labeled 
MMP-activatable PET probe has been developed to overcome the 
lack of specificity of inhibitor-based probes (112). Photoacoustic 
tomography (PAT or PAI) (58, 113, 114) combines ultrasonic 
resolution with electromagnetic-enhanced contrast to obtain 
quantitative information on tissue structure, blood flow, and 
perfusion, and, through targeted probes (59), on receptor status 
or enzyme activity. For example, a photoacoustic probe activated 
by MMP-2 and MMP-9 demonstrated sensing of MMP-2/-9 
activity in a follicular thyroid carcinoma model (115). With 
an imaging depth of >30 mm, depending on setup and desired 
spatial resolution (58), PAT expands on the tissue penetration 
of up to 20 mm typical for optical imaging (51, 108) and is thus 
suitable to monitor non-invasively tumor characteristics in 
orthotopic preclinical cancer models. The lack of anatomical/
morphological information inherent to optical imaging, PAT/
PAI, and PET/SPECT can be overcome by multimodal imag-
ing. Using fluorescence molecular tomography (FMT) (51) 
coregistered with MRI, Salaun et  al. (116) found increasing 
MMP-13 levels as lung tumors progressed. In skin squamous cell 
carcinoma xenografts, MMP-2, -3, -7, -9, -12, and -13 activities 
correlated with degree of angiogenesis and tumor invasion, as 
imaged by FMT combined with μCT (117). PAT/PAI, combined 
with US and OCT, can provide non-invasively morphological 
and functional tumor characteristics (60). Molecular MRI to 
measure MMP activity using protease-modulated CAs is still 
emerging and is hampered by its insensitivity, requiring long 
acquisition times but is potentially quantitative, and anatomical 
information can be obtained in the same setting (108, 109). Of 
FiGURe 4 | Different motility and invasion of low-metastatic, GFP-expressing (green) and high-metastatic, CFP-expressing (white) mammary  
tumor cells within the collagen network (purple) was imaged by in vivo intravital microscopy with FL and second-harmonic generation. Bars 25 µm. 
(A) Time series demonstrating the migration of GFP-expressing (arrow head) and CFP-expressing (arrow) tumor cells along collagen fibers. (B) Metastatic growth of 
color-coded cells in the lung. (C) Protruding filopod (arrow, left) and lamellapod (arrow, right) of CFP-expressing cell near GFP-expressing cells. (D) Overall, the 
high-metastatic cells (outlined in white) move more frequently (see orange arrow path) than the low-metastatic cells (green). Adapted with permission from Ref. (67).
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note is that the interpretation of MMP images obtained with the 
typically broad-spectrum probes (110) is further complicated 
by the function of MMPs in biological processes beyond ECM 
remodeling (111).
Proteoglycan (Hyaluronan) Imaging
Another major ECM constitutent, the proteoglycan hyaluronan 
[hyaluronic acid (HA), hyaluronate] is a high molecular weight 
glycosaminoglycan with a significant role in tumor growth and 
metastasis (118, 119), acting as tumor suppressor or promoter 
depending on its molecular weight (120).
It is degraded by hyaluronidases (Hyals), with hyaluroni-
dase-1, -2 (Hyal1, Hyal2) currently being the most studied in 
cancer (119). Hyal1 overexpression has been associated with 
more aggressive tumors in a variety of epithelial cancers (e.g., 
bladder, colorectal, breast, and ovary), while Hyal2 may function 
as a tumor suppressor or promoter (119). The development of 
various HA probes to image HA turnover and clearance and of 
theranostic HA probes where encapsulated drugs are released in 
response to Hyal activity (119, 121, 122) has expanded greatly 
in recent years, and a detailed review is beyond the scope of this 
paper. HA probes often exploit the high specificity of HA for the 
CD44 receptor, a transmembrane receptor overexpressed in many 
tumor cell types (120, 121, 123–134). Single moiety, HA-based 
CAs have been used to image Hyals activity by MRI (135) and 
NIRF (124). Fluorescence correlation spectroscopy and Forster 
resonance energy transfer of HA-conjugated probes have shown 
promise in quantitative bladder cancer staging by detecting shed-
ded Hyals in urine samples (119). Also, fluorescent HA probes 
may be used in an intraoperative to assess Hyal activity or drug 
delivery of theranostic probes (119). Often, HA probes contain 
more than one CA moiety to harness the strength of multimodal 
imaging, such as MRI/optical imaging (123, 136), MRI/computer 
tomography (CT) (137), NIRF/CT (138), or NIRF/PA imaging 
(139–141) to improve diagnostic capability and monitoring of 
therapeutic efficacy (121, 142).
FiGURe 5 | intravital microscopy of the tumor blood vessels, lymph 
vasculature, and vascular response to treatment. (A) Top: Z-stack of 
lymphatics detected by near-infrared fluorescence (NIRF) multiphoton 
microscopy of FITC-tagged LyP-1 peptide (green), collagen fibers detected 
by second-harmonic generation, and tumor cells imaged by epifluorescence 
of cytoplasmic DsRed2 (red) and nuclear histone 2B (H2B)-EGFP (green) 
shows lymph vessels at the tumor margin. Bottom: intralymphatic (white 
arrowheads) and perilymphatic (black arrowheads) invasion of fibrosarcoma 
cells expressing cytoplasmic DsRed2 (red) and H2B-EGFP (green). Bars 
100 µm. Adapted with permission from Ref. (66). (B) In vivo optical frequency 
domain imaging of blood [depth denoted from red (up to 2 mm deep) to 
yellow (superficial)] and lymph (blue) vessels in control and DC101-treated 
tumors, depicting the antivascular effect of VEGFR-2 inhibition. Adapted with 
permission from Ref. (68).
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whose expression increases with epithelial–mesenchymal transi-
tion, is typically targeted to image tumor-associated angiogenesis 
(143, 144). Laminins are a family of glycoproteins which interact 
with other ECM proteins, assuring the ECM organization, and 
are involved in cellular signal transduction pathways (145), cell 
adhesion, migration, and proliferation (146) and thus affect in 
cancer, tumor invasion, angiogenesis, and metastasis (145, 147). 
While laminins and their function have been studied extensively 
in vitro or ex vivo (29, 148–150), in vivo studies directly imaging 
laminins have been limited. Cuesta et al. developed a fluorescent 
trimerbody recognizing an angiogenesis-associated laminin 
epitope, accumulating in tumors (151). Other studies have used 
imaging agents targeting laminin cell surface receptors directly or 
indirectly to detect or treat tumors (152–154).
Mesenchymal Stromal (Stem) Cells 
(MSCs), Cancer-Associated Fibroblasts 
(CAFs), and immune Cells
By tumor cells recruited adult, multipotent, non-hematopoietic 
stem cells (mesenchymal stromal (stem) cells, MSCs), typically 
derived from adipose tissue and bone marrow, have been found 
to differentiate into osteoblasts, CAFs, and pericytes among 
other cell types (155). In tumors, MSCs may contribute to tumor 
initiation, progression, angiogenesis, and metastasis, while also 
impacting immune function (155).
Cancer-associated fibroblasts are fibroblasts that reside within 
the tumor or tumor margins (156). They promote tumorigenic 
features, such as drug resistance, ECM modulation, chronic 
inflammation, and invasiveness (156). They may originate from 
normal fibroblasts or smooth muscle cells (altered by tumor 
cells), bone marrow-derived stem cells (mesenchymal stromal 
(stem) cells, MSCs), recruited and altered by tumor cells, or 
epithelial cells through transdifferentiation to myofibroblasts, or 
endothelial cells through endothelial-to-mesenchymal transition 
(156–158).
The TME (Figure  1) includes various immune cells: innate 
[tumor-associated macrophages (TAMs)], neutrophils, mast 
cells, myeloid-derived suppressor, dendritic, and natural killer 
cells, and adaptive (T and B lymphocytes), with TAMs and T cells 
the most prevalent cell types (159). Immune cells may enhance 
tumor growth and metastasis or exhibit antitumor immunity by 
modulating the immune and inflammatory milieu in the TME 
through paracrine and autocrine cell interactions, and thus, 
affecting the production of pro-angiogenic and growth factors, 
proteases, recruitment of other hematopoietic cells, or release of 
reactive oxygen or nitrogen species (159, 160). Immunotherapy 
aims at enhancing the antitumor activity of tumor-associated 
immune cells (161).
MSC Imaging
In preclinical cancer models, the preferential homing of ex vivo 
cultured MSCs to tumor tissue and metastasis has been imaged 
non-invasively in  vivo after intravenous/arterial injection of 
MSCs, pre-(multi-)labeled with bioluminescence (162–167), 
fluorescence (168), MRI (169–171), PET (170–173), or SPECT 
(171, 174) imaging probes (175). The tumor effects and/or 
Other ECM Constitutents
Only a few studies report the in vivo imaging of other ECM con-
stituents, such as fibronectin or laminins, in cancer. Fibronectin, 
FiGURe 6 | In vivo immune cell imaging. (A,B) Specificity of in vivo imaging of immune cells in 4T1 mammary breast tumors by fluorescence-reflectance imaging 
with a Cy5.5-labeled polyclonal antibody against murine S100A9 (aS100A9-C5.5). (C) Fluorescence molecular tomography of coinjected rabIgG-Cy7 and 
aS100A9-C5.5 demonstrates homogeneous perfusion (left) and immune cell distribution (right), respectively. (D) Ex vivo validation shoe S100A+ cells in the tumor 
periphery corresponding to F4/80+ TAMs. Adapted with permission from Ref. (69) © by the Society of Nuclear Medicine and Molecular Imaging, Inc.
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localization of MSCs, pre-labeled with an imaging probe and 
coinjected with tumor cells, have been monitored in  vivo with 
MRI (176) and bioluminescence (177–180) imaging. The prefer-
ential accumulation of MSCs at sites of inflammation and tumors 
makes them an ideal vehicle for treatment delivery (155, 181, 
182), and combined treatment/imaging MSC moieties are being 
developed for cell tracking and treatment monitoring (175, 177, 
178, 183). While overall safe clinically (175, 184), ex vivo culture 
and pre-labeling of MSCs may lead to secondary tumors (185) 
and/or impact functionality (186). Using fluorescent, transgenic 
mice (187), potentially avoids ex vivo culture and pre-labeling of 
MSCs, with the disadvantage that typically all cell types express 
the imaging marker, limiting the in vivo identification of different 
stromal cell types, unless pre-labeled.
CAF Imaging
Various markers, such as α-smooth muscle actin (α-SMA), 
vimentin, and fibroblast-activation protein α (FAP), have been 
used to identify CAFs (188). In preclinical models, CAFs have 
been shown to promote breast tumor growth and metastasis 
by enhancing the recruitment of immune suppressor cells and 
TAMs (189) and to mediate collagen remodeling (190). The high 
expression of FAP in CAFs (191, 192) makes it a desirable target 
for diagnostic and therapeutic imaging, although it may also be 
expressed in some other tissues and tumor cells (192–194). One 
difficulty for the development of FAP-targeted in  vivo imaging 
probes is that FAP shares peptide substrates with other post-
prolyl peptidases, resulting in non-specific binding in vivo (192). 
Thus to track CAFs in  vivo by MRI or NIRF imaging, Granot 
et al. took advantage of caveolae-mediated endocytosis in fibro-
blasts by pre-labeling CAFs in vitro with the CAs biotin-bovine 
serum albumin-gadolinium diethylenetriaminepentaacetic acid, 
Feridex, or 1,1′-dioctadecyl-3,3,3-tetramethylindotricarbocya-
nine iodide (195, 196). Recently developed FAP-specific, activat-
able NIR fluorescence probes (193, 194) show promise in in vivo 
imaging of FAP-expressing tumors. And novel cancer treatments 
FiGURe 7 | in a carcinoembryonic antigen (CeA)-expressing 
colorectal adenocarcinoma model, simultaneous magnetic resonance 
imaging (MRi)/positron emission tomography (PeT) at 4 h and 20 h 
after the injection of a radiolabeled antibody against CeA (64Cu-
DOTA-NHS-M5A) demonstrates its accumulation in the tumor over 
time, while the apparent diffusion coefficient across the tumor 
remained largely unchanged. Adapted with permission from Ref. (70)  
© by the Society of Nuclear Medicine and Molecular Imaging, Inc.
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based on the depletion of FAP-expressing stromal cells would 
greatly benefit from monitoring response in vivo with improved 
multimodal imaging probes (197).
Immune Cell Imaging and Monitoring of 
Immunotherapy
Multiple recent reviews summarize the imaging techniques 
applied to track various immune cell types in vivo and to moni-
tor immunotherapy response, including the ability to optimize 
administration route of therapeutic immune cells (45, 47, 61, 63, 
198–202).
To visualize immune cells in  vivo, cells may be labeled ex 
vivo with paramagnetic, fluorescent, or radiochemical probes 
for MRI, FLI, or PET/SPECT respectively or transfected with 
reporter genes for PET, SPECT, bioluminescence imaging (BLI), 
and/or FLI (or FMT) before injection into the host (45, 198, 201, 
203–206). Tumor-infiltrating lymphocytes, dendritic cells (DCs), 
or TAMs can be imaged by FLI or PET/SPECT, using fluores-
cently labeled (Figure 6) or radiolabeled antibodies or antibody 
fragments targeting cell-type specific surface receptors (198, 199, 
201). Delivery of full-size antibodies may be affected by vascular 
dysfunction in tumors, thus, potentially affecting image quality 
and interpretation [false positives, reduced specificity (50)]. 
Targeted US microbubbles have been used to track B7-H3 express-
ing TAMs and tumor cells (198). The high endocytic activity of 
TAMs facilitates their imaging by MRI, PET, and to a lesser extent 
by CT, FLI, US, Raman imaging, or PAI, using nanoparticles, 
either uncoated (e.g., ultra-small superparamagnetic iron-oxide 
nanoparticles for MRI) or coated to increase macrophage affinity 
(199, 200). Nanoparticle uptake may vary across different mac-
rophage populations and may be detected also in other cell types 
(e.g., tumor cells) to a variable degree, confounding potentially 
macrophage tracking, but has been used successfully in clinical 
lymph node cancer staging by MRI (200). Cellular MRI of DC 
migration using CAs (iron oxide-based nanoparticles, perfluoro-
carbon emulsions) permits repeated monitoring (a limitation in 
PET/SPECT) and does not require pre-labeling with reporter 
genes, as in BLI or FLI, but has lower sensitivity (63). Intravital 
microscopy of stroma–tumor cell dynamics (207) has been an 
essential tool in assessing lymphocytic interactions in tumors 
and draining lymph nodes by optical imaging (208). The clini-
cal translatability of these imaging methods has been reviewed 
previously (202, 209), with optical methods currently limited to 
intraoperative imaging (50).
Tumor vasculature and Lymphatics—
endothelial Cells and Pericytes
Endothelial cells line the inside of tumor blood vessels and lym-
phatics and interact with pericytes and vascular smooth muscle 
cells in the vessel wall (Figure 1) (210–212). Cancer-associated 
endothelial cells often display an enhanced angiogenic potential 
(211), due to proangionenic factors secreted from cancer cells 
and/or tumor–stroma cells, forming heterogeneous neovascula-
ture of enhanced permeability (6). The role of pericytes in tumor 
vascular development is still largely unexplored (212).
Tumors outgrowing their vascular supply lead to constant 
vascular remodeling, acute and permanent hypoxic tumor areas, 
and nutrient deprivation (23, 45, 213), increasing treatment 
resistance (due to, e.g., reduced radical formation in hypoxic 
tumor areas affecting radiotherapy and limiting drug delivery of 
chemotherapeutics) (214–216).
Imaging of Tumor Vascularity
Vascular function and distribution has been assessed in vivo non-
invasively by MRI (45, 217–226), CT (μCT) (45, 52, 227, 228), 
H215O or 11C PET (45, 217), US (45, 52, 229) [clinical (230)], PAI 
(45, 58, 114), and intravital optical imaging methods (231), such 
as FLI (48), second-generation OCT [optical frequency domain 
imaging (OFDI)] (Figure 5) (45, 48, 52, 68), and FMT (45).
In vascular MRI, five acquisition methods are used to 
measure the enhancement of exogenous (i, ii) or endogenous 
(iii–v) contrast dynamically: (i) Dynamic contrast-enhanced 
(DCE)-MRI, which exploits the shortening of the T1 relaxation 
time of water protons near a CA, typically Gd-based and low 
molecular weight (223, 229), (ii) dynamic susceptibility contrast 
(DSC)-MRI, which measures the effect of the CA (e.g., Gd-based 
CA or superparamagnetic iron oxide particles) on the T2 and T2* 
relaxation time of nearby water protons (218, 222), (iii) arterial 
spin labeling (ASL)-MRI, where the dynamic measurement of 
the in- and out-flow of magnetically labeled water protons, which 
serve as endogenous “CA,” characterizes the vasculature in a 
region of interest (223, 232), (iv) blood oxygen level dependent 
MRI (BOLD-MRI) where oxyhemoglobin confers diamagnetic 
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and deoxyhemoglobin paramagnetic contrast, respectively (223), 
and (v) diffusion-weighted MRI (DW-MRI), where intravoxel 
incoherent motion (IVIM) reflects vascular perfusion (64, 224, 
229, 233, 234).
In DCE- and DSC-MRI, the first pass of the exogenous CA 
uptake is characterized by the venous or arterial input function 
(219, 220, 222, 235–237), after which the CA distributes through-
out the vasculature, extravasates at sites of leaky blood vessels into 
the interstitium, and is ultimately cleared from the body. Rate 
and path (e.g., liver and kidney) of tissue and vascular clearance 
are dependent on the specific CA (e.g., size and type of CA) 
used (223, 225, 238). Hemodynamic parameters, such as vessel 
density, vascular permeability, vascular perfusion, extravascular 
space, vessel size and plasma volume, etc., are either derived from 
semiquantitative measures of signal enhancement (220, 239–241) 
or from pharmacokinetic modeling of signal-versus-time curves 
(222, 242) with the underlying principle based on standard tracer-
kinetic theory of linear and stationary systems (221, 243) and the 
model adjusted to account for variations of CA characteristics, 
e.g., low versus high molecular weight (impacting the ability of 
the CA to extravasate), receptor targeted (e.g., ανβ3-integrin), 
extra- or intracellular or both, with exchange (218, 223, 235, 
244). More recently vascular feature-based analyses have been 
developed to assess intratumor vascular heterogeneity (245, 246).
Hemodynamic parameters conferred from ASL- and BOLD-
MRI are tissue blood flow and volume (223, 232). Tissue perfu-
sion and diffusivity are obtained from IVIM DW-MRI by fitting 
data with a bi-exponential model (224).
Similarly to DCE-MRI, DCE-CT has been used clinically 
to obtain blood flow, blood volume, and permeability with the 
disadvantage of radioactivity limiting serial monitoring and often 
worse spatial resolution than DCE-MRI (227, 228). In preclinical 
models, the relatively high radiation dose of μCT limits its in vivo 
use (45), and vascular networks have been assessed ex vivo (247). 
Viscosity of CA for DCE-CT may also result in complications, 
such as vessel rupture, and DCE-μCT still suffers from artifacts 
generated from, e.g., bones or large vessels (52). Generally, func-
tional vascular parameters similar to DCE-MRI can be extracted 
from DCE-μCT data (52, 248).
While H215O PET measures specifically tissue perfusion 
(217), the short half-life of 15O limits the applicability of vascular 
perfusion measurements by PET (45). Vascular permeability 
can be obtained from dynamic PET using the macromolecular 
CAs 68Gd-DOTA-albumin (45), 11C-methylalbumin (limited by 
the 20.4  min short half-life of 11C), or 68Ga-transferrin (217). 
However, lack of accompanying anatomical information and ion-
izing radiation limits (especially serial) vascularity measurements 
by PET, despite its potential higher sensitivity than DCE-MRI 
and its ability to directly measure tissue perfusion.
Tumor angiogenesis, i.e., perfusion and vascular density 
have been successfully measured in small animals by Doppler 
or contrast-enhanced US with microbubbles (non-targeted and 
targeted to, e.g., VEGFR2 (249), ανβ3-integrin, or endoglin) with 
a spatial resolution of ~50–100 μm (45, 52, 229). One advantage 
of the combining contrast-enhanced and non-contrast-enhanced 
high-frequency volumetric power Doppler US is the ability to dis-
tinguish mature and immature vessels (52). While US is cheaper 
than DCE-MRI, it is not suitable for whole-body imaging, has 
limited soft tissue contrast, and is to some extent user dependent, 
limiting its applicability, especially for monitoring of antiangio-
genic treatments (52).
In PAI of tumor angiogenesis, the intrinsic contrast from 
hemoglobin permits visualization of microvasculature and quan-
tification of blood oxygen saturation (45, 52), with its usefulness 
recently extended to flow imaging (114). Submillimeter resolution 
is achieved, albeit restricted to depth of a few centimeters (58). 
Reporter genes or endogenous targeted CAs extend the ability to 
visualize and quantify tumor angiogenesis in vivo (52). The hemo-
dynamic response to external stimuli or treatment is quantified 
from contrast changes after image reconstruction (52, 58, 114).
Blood vessel diameter, surface area, and branching pattern 
have been assessed with intravital optical imaging methods during 
tumor growth and/or treatment (Figure 5) (45, 48, 52, 68, 231).
Imaging of Lymphatic Tumor Vasculature
Imaging of the lymphatic system is here summarized only briefly, 
as is has been reviewed in detail previously (50, 250). The lymphatic 
system (Figure 1) drains lymph fluid from interstitial space to the 
venous circulation, thus, maintaining tissue fluid homoeostatis, 
transports immune cells to lymphoid organs, and plays a role in 
lipid absorption (50, 250). While the lymphatic vasculature near 
tumors provides a route for metastatic dissemination of cancer 
cells, its role has only been explored by non-invasive imaging 
methods over the past decade (50, 250). Lymphangiography 
traces the drainage of a CA for X-ray, CT, MRI, US, PAI, or opti-
cal imaging but is lacking specificity, requiring direct injection 
into a lymph vessel (difficult to perform in preclinical models) or 
intradermal injection near sites draining into the dermal capillary 
plexus (50, 250). Identifying sentinel lymph nodes containing 
cancer cells has been achieved with intravenously injected CAs 
that identify blocked drainage or directly target cancer cells (50). 
In vivo OCT (or OFDI) and laser speckle imaging permit CA-free 
visualization of lymphatics (Figure 5) (68, 250). The most specific 
imaging approach to identify and characterize the lymphatic 
system is to use CAs, targeted to lymphatic vascular-specific 
molecules, i.e., vascular endothelial growth factor receptor-3 
(VEGFR-3), lymphatic vessel hyaluronan receptor-1 (LYVE-1), 
podoplanin, or prospero-related homeodomain transcription 
factor PROX1, with LYVE-1 the most widely used lymphatic 
endothelial cell marker (250). LYVE-1-targeted CAs have been 
developed for PET (251) and optical imaging (252). Preclinically, 
fluorescent or bioluminescent gene reporters in transgenic mouse 
models have been also been used to visualize lymphatics, typically 
by intravital imaging methods (50).
Metabolic imaging
Metabolic reprograming during tumor development and 
progression leads to a characteristic in  vivo tumor meta-
bolic phenotype (see Section “Introduction—The Tumor 
Microenvironment”).
Choline-Phospholipid Metabolism
Changes in choline-phospholipid metabolism have typically been 
assessed preclinically (and clinically) by non-invasive 31P and 1H 
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magnetic resonance spectroscopy or spectroscopic imaging (MRS 
or MRSI) (14–16, 18, 253). Choline uptake and metabolic conver-
sion have also been assessed with high sensitivity by 18F-fluoro-, 
3H-, or 11C-choline PET and successfully translated to the clinic 
(254–257). As with any PET tracer though, radiolabeled choline 
PET does not discriminate between different metabolites (256), 
limiting its value for pathway studies.
Hypoxia
Tumor hypoxia has been imaged non-invasively and visualized 
directly by hypoxia markers accumulating in hypoxic cells using 
PET, electron paramagnetic resonance (EPR), or 19F MRS (65, 
248, 258–266). Delivery of a specific hypoxia marker to less 
vascularized regions, which are typically associated with hypoxia, 
may impact the intensity of the accumulating hypoxia marker 
(246, 267). Since evolution of chronic or acute hypoxia in tis-
sue is linked to the vascular delivery of oxygen, several indirect 
MRI methods based on vascular features associated with tumor 
hypoxia, such as BOLD, TOLD, or DCE-MRI, have been devel-
oped to identify hypoxic areas or hypoxia changes in tumors (64, 
246, 268–271). Tissue oxygen tensions have been mapped by 19F 
MRI oxymetry using perfluorocarbons; as with any exogenous 
tracer, these measurements are vascular delivery dependent, 
and thus, potentially biased toward well-perfused tumor regions 
(271). While carbonic anhydrase-IX (CA-IX) has been proposed 
as an intrinsic hypoxia marker in tumors, CA-IX expression, 
measured by immunohistochemistry, correlated to hypoxia in 
some and not in other studies (260). Nevertheless, attempts are 
underway to image CA-IX expression in vivo by PET (272), NIRF 
(273), and SPECT (274).
Glycolysis and Lactate
Tumor glycolysis is typically assessed by in vivo PET using the cel-
lular entrapment of 18F-FDG, after uptake of 18F-FDG by glucose 
transporters (GLUT-1, GLUT-3; often overexpressed in cancer) 
and subsequent phosphorylation by hexokinase II (256, 275). 
While it is quite insensitive, 13C MRS has been applied preclinically 
to evaluate glycolysis and the 13C labeling of downstream metabo-
lites (275–277). Detection sensitivity of 13C MRS can be signifi-
cantly improved by magnetization transfer techniques or indirect 
inverse detection (276, 277). Hyperpolarization of 13C-labeled 
substrates increases detection sensitivity up to 10,000-fold, with 
the caveats that the hyperpolarization is short lived and currently 
limited to few substrates, including glucose (64, 275, 276, 278, 
279). Compressed sensing can further improve acquisition speed 
and spatial resolution in hyperpolarized (HP) 13C MRSI (280). 
Lactate production from precursors, such as 13C-labeled pyruvate 
or glucose, can be rapidly assessed globally and localized by HP 
13C MRSI (278, 279). Steady state levels of tumor lactate have been 
assessed by 1H MRS and MRSI, using spectral editing methods 
to suppress the high lipid signal overlapping lactate (64, 275, 
281–285).
pH
Measuring tumor tissue pH non-invasively is challenging, and 
various methods have been and are being developed to measure 
preclinically extracellular and/or intracellular pH (pHe or pHi) 
(64, 286).
Tumor pHe and pHi distributions can be obtained by 31P MRS/
MRSI using 3-aminopropylphosphonate (287, 288). However, 
insensitivity of 31P MRSI limits its spatial resolution and restricts 
broad applicability. Thus, 1H MRSI pHe markers have been 
developed to improve detection sensitivity (288–291). To shorten 
acquisition times and improve sensitivity further, with potential 
for clinical translation, HP 13C MRSI of injected bicarbonate has 
been proposed for pH imaging, with pH (predominantly pHi, 
though it does not distinguish between pHi and pHe) calculated 
from the signal intensity ratio of hyperpolarized H CO13 3
−  to 
13CO2 (292, 293). However, the reaction is dependent on CA-IX 
activity in the tissue, thus, calibration has to be performed for 
each tissue type separately, restricting its applicability (294). 
Chemical exchange saturation transfer (CEST) MRI detects the 
pH-dependent chemical exchange between an amide proton and 
surrounding water molecules (291, 295). In acidoCEST, the pH 
dependence of the CEST effect ratio of a CEST agent with two 
amide protons, generating two CEST effects, is used to measure 
pHe (295–297). Challenges to measure pH by acidoCEST include 
its low sensitivity, requiring optimization of experimental param-
eters (295), and it may not always be a given that the CEST effect 
is solely visible for the amide protons of the selected CEST agent 
and only affected by pH (291).
Recently, the pH-dependency of cellular membrane insertion 
of radiolabeled pH (low) insertion peptides has been used to 
image tumor pH (at the intra-/extracellular interface) preclini-
cally with PET (298–301).
Other non-invasive imaging modalities assessing pH in vivo 
include optical imaging with pH-sensitive dyes (302–304) 
or a pH-sensitive reporter gene (305), ratiometric PAI with 
pH- sensitive nanoprobes (306, 307), MRI using a CA with 
pH-sensitive (and concentration-dependent) relaxivity, with the 
difficulty of measuring in vivo the CA concentration (291), and 
EPR spectroscopy (308, 309).
Additionally, pH-sensitive probes are being developed as 
theranostic agents, combining treatment with diagnostic and 
monitoring ability (310–314). Of note is that all exogenous pH 
markers are delivery dependent and may not be clinically trans-
latable, adding further challenges to pHe/pHi imaging.
NON-iNvASive MULTiMODAL iMAGiNG 
OF TUMOR–STROMA iNTeRACTiON
Here, after a brief overview and some examples of recently rec-
ognized tumor–stroma interactions (see Section “Tumor–Stroma 
Interactions”), ongoing efforts to apply directly non-invasive mul-
timodal imaging to characterize and understand tumor–stroma 
interaction in the context of tumor development, progression, 
and treatment will be summarized (see Section “Non-invasive 
In Vivo Imaging of Tumor–Stroma Interactions”). As is evident 
from the comparably fewer studies (see Section “Non-invasive 
In Vivo Imaging of Tumor–Stroma Interactions”), it is much more 
challenging to image directly and non-invasively the tumor–
stroma interaction in in  vivo cancer animal models (237, 315) 
and to confirm in vitro and ex vivo findings.
11
Ramamonjisoa and Ackerstaff Non-invasive Imaging: TME, Tumor-Stroma Interaction
Frontiers in Oncology | www.frontiersin.org January 2017 | Volume 7 | Article 3
Tumor–Stroma interactions
Tumor stroma interactions focus on the complex crosstalk 
between cancer and stromal cells and cell interactions with the 
ECM (316–320). These interactions are mediated by chemokines, 
soluble factors from enzymes, growth factors, extracellular 
vesicles (e.g., exosomes) and/or microRNAs, etc., and regulate 
enzymes activities, expression of genes and proteins, and meta-
bolic pathways involved in tumor growth, metastases, survival, 
and drug resistance (37, 188, 211, 319–325). In this section, we 
present selected examples of in vitro, ex vivo, and in vivo tumor 
growth studies that highlight tumor–stroma interactions by using 
preclinical models that attempt to incorporate/simulate microen-
vironmental conditions of ultimately clinical relevance.
Various in vitro models mimicking the TME, such as cocul-
tures between stromal and tumor cells or CAF-derived exosomes 
and cancer cells (326), 3D culture systems (327), bioreactors 
for live cell studies (20, 277, 328–330) have been developed 
to understand the nature and mechanisms behind tumor– 
stroma interactions by, e.g., gene expression microarrays from 
cocultures (331).
For example, in in vitro 2D and 3D cultures of the two breast 
cancer cell lines MDA-MB-231 and MCF-7 cocultured with 
CAFs or control fibroblasts, CAFs promoted invasion and prolif-
eration in both MDA-MB-231 and MCF-7, and the more invasive 
MDA-MB-231 increased α-smooth muscle actin (α-SMA, a 
marker of fibroblast-to-myofibroblast transition) expression of 
CAFs contrary to the non-invasive MCF-7 (332), demonstrating 
reciprocal interaction. In cocultures of the cervical cancer cell 
line CSCC7 with CAFs or control fibroblasts, increased CSCC7 
migration was associated with a CAF-induced decrease and 
partial replacement of fibrillar ECM components with laminin-1 
(148). In 3D cocultures of oral tongue squamous cancer cells 
and CAFs in matrigel, CAFs (and CAF-conditioned medium) 
promoted growth, proliferation, migration, and epithelial-to-
mesenchymal transition of the cancer cells (333). As observed 
by OCT, 3D cocultures of breast cancer cells and immortalized 
fibroblasts induced larger and more spherical acini with increased 
lumen size than cocultures using immortalized breast cells (101). 
Besides CAFs, the presence of TAMs has been shown also to 
affect ECM remodeling (334). For example, excretion of MMPs 
into the supernatant increased significantly in coculture of two 
breast cancer cell lines and macrophages, enhancing tumor cell 
invasiveness, and not in the benign breast cell line/macrophage 
coculture (335).
Tumor cells and CAFs also interact metabolically (Figure 2). 
As shown in  vitro, CAFs take up and metabolize extracel-
lular lactate (38) and export pyruvate which is taken up and 
metabolized by cancer cells (336) (Figure  2). Other research 
implies that epithelial cancer cells use metabolites, such as 
lactate, ketone bodies, and glutamine, excreted by CAFs in 
response to cancer cell-induced oxidative stress (39, 334, 337) 
(Figures 1 and 2). Glycolysis and glutamine-dependent reduc-
tive carboxylation increased in cancer cells following oxidative 
phosphorylation (OXPHOS) inhibition induced by exposure to 
CAF-derived exosomes (326). Additionally, immune cells and 
adipocytes may further impact the metabolic tumor phenotype 
(334). Closer to the in  vivo scenario, ex vivo tumor/stroma 
immunostaining, molecular profiling from tissue microarrays 
of excised tumors (338), or multiplexed staining and in  situ 
transcriptome profiling techniques (339) improve further our 
understanding of tumor–stroma interaction. For example, Choi 
et al. (338) classified breast cancer subtypes of patient tumors 
into four subgroups defined by the ex vivo expression of the gly-
colysis markers Glut-1 and/or CA-IX in the tumor and stroma, 
respectively: Warburg type (tumor: GLUT-1 and/or CA-IX 
positive; stroma: Glut-1 and CAIX negative), reverse Warburg 
type (tumor: Glut-1 and CAIX negative; stroma: GLUT-1 and/or 
CA-IX positive), mixed type (tumor and stroma: GLUT-1 and/
or CA-IX positive), and null type (tumor and stroma: Glut-1 
and CAIX negative). The Warburg and mixed type were pre-
dominantly associated with triple-negative breast cancer, while 
the reverse Warburg and null-types predominantly associated 
with luminal breast cancer (338).
These data/models of metabolic interaction between cancer 
cells and CAFs or other stromal cells highlight the complexities 
of metabolic crosstalk and the need for further research to under-
stand how metabolic plasticity of tumor and stromal cells benefit 
tumor progression and evasion of treatment.
While MSCs can dedifferentiate into various stromal cells after 
recruitment to tumors, many questions about the mechanisms 
of MSC homing and MSC–cancer cell interaction are still top-
ics for future research (155). In a recent study, MSCs promoted 
in  vivo growth of subcutaneous colorectal tumor models by a 
β1-integrin-dependent interaction of MSCs and cancer cells 
(340). Coinjection of breast or prostate cancer cells with either 
normal fibroblasts or CAFs into animal models showed that, 
compared to normal fibroblasts, the presence of CAFs enhanced 
tumor growth (341, 342) and, as shown for the breast model, 
increased angiogenesis through elevated stromal cell-derived 
factor 1 via recruitment of endothelial progenitor cells (341). 
As demonstrated by in  vivo fluorescence imaging and caliper 
tumor volume measurements, coinjection of human endometrial 
cancer cells with CAFs into nude mice increased tumor growth 
compared to tumor initiation without coinjection of CAFs (343). 
It was shown that the proliferation of endometrial cancer cells 
was increased in the presence of CAFs through the activation of 
JAK/STAT3/c-myc pathway (343).
Tumor–stroma interactions may sensitize tumors to treat-
ment or be a source of treatment resistance across a wide range 
of therapeutics (320). And targeting tumor–stroma interactions 
by targeting its mediators, such as chemokines, may improve 
treatment response. For example, as observed with BLI, treat-
ment of a prostate cancer model with the CXCR4-specific 
inhibitor AMD3100 in combination with docetaxel significantly 
reduced tumor growth compared to docetaxel alone (344). As a 
high-throughput alternative to in vivo models, an in vitro tumor 
cell-specific bioluminescence imaging (CS-BLI) assay for tumor–
stroma cell cocultures has been proposed (345). Using this assay, 
it was shown that multiple myeloma cells exhibited chemoresist-
ance to dexamethasone and doxorubicin when cocultured with 
bone marrow stromal cells, while effectiveness of reversine was 
enhanced by the presence of stromal cells (345).
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Novel treatments, targeting tumor–stroma interaction by 
therapeutic targeting of adhesion, proteolysis, and/or signaling 
pathways, may improve on current treatment regimens and 
overcome treatment resistance (2, 346).
Non-invasive In Vivo imaging of  
Tumor–Stroma interactions
Studying tumor–stroma interactions in  vivo enables the com-
prehensive characterization of the TME and its impact on treat-
ment efficacy, potentially leading to improved diagnosis, to the 
identification of new treatment targets, and closing further the 
gap between preclinical and clinical studies (320). While single 
imaging methods have been used to image different aspects of 
the TME, only recently multimodal imaging has become more 
frequent. One major challenge of imaging the TME is that tumor 
and stromal cells use common pathways (286), necessitating 
cell-type-specific labeling and ideally imaging with cellular reso-
lution. Localized, high-resolution imaging or combining multiple 
imaging modalities may to some extent overcome this inherent 
challenge. Intravital microscopy (66), which is considered a 
minimally invasive imaging modality, provides high-resolution 
imaging, including imaging of cellular processes (86, 208, 347), 
and has been to date the method of choice to study cancer cell 
interaction with the TME (Figures 3–5).
By using transgenic mice expressing green fluorescent protein 
(GFP) in all cells or in specific organs or driven by a cell marker 
and tumor cells expressing red fluorescent protein (RFP) (237, 
348) or GFP in the nucleus and RFP in the cytoplasm (349), 
whole-body fluorescence imaging has been used to study tumor–
TME interactions. While morphology and location of cells may 
help to identify what type of stromal cell may be involved in a 
specific biological process (237), specificity is lacking as all cell 
types of the host express the same fluorescence and ex vivo studies 
are needed for confirmation (349). By ex vivo validation of cell 
types, it was confirmed in a GFP-expressing mammary tumor 
model and a host with GFP-expressing macrophages, that both, 
cancer cells and macrophages migrated into microneedles filled 
with EGF, TGF-alpha, and CSF-1, as detected by multiphoton 
intravital microscopy (350). Using these techniques, it has been 
shown that paracrine loops associated with macrophage and 
tumor cell interaction impact tumor cell migration, intravasation, 
and dissemination (351).
Using intravital microscopy with multiphoton laser scanning 
microcopy (LSM) and SHG imaging of a human soft tissue sarcoma 
in VEGF-GFP mice, increased ECM remodeling by CAFs after 
exposure to relaxin has been imaged in vivo, with the involvement 
of CAFs confirmed by ex vivo cell typing (352). Using human, 
DsRed2- and nuclear histone 2B (H2B)-EGFP-expressing fibro-
sarcoma cells implanted into deep dermis of nude mice, tumor 
growth and tumor cell invasion into the surrounding tissue could 
be imaged by epifluorescence microscopy (Figure 3A) (66). In the 
same tumors, morphology (including collagen fibers), neoangio-
genesis, cancer cell mitosis, and apoptosis were assessed in vivo 
during tumor growth by intravital microscopy with FLI and SHG 
(Figure  3B) (66). Multiphoton LSM combined with collagen 
(SHG) imaging of murine mammary tumors grown from a mix 
of a low-metastatic cell line expressing GFP and a high-metastatic 
subline transfected expressing CFP (cyan fluorescence protein) 
in the cytoplasm has been used to track and visualize cell shape, 
subcellular structures, and behavior in vivo (67) (Figure 4). The 
motility of the cells with the larger metastatic potential was about 
4.5-fold higher than in the cells with low-metastatic potential 
with migration along collagen fibers (67).
Beyond migration and imaging of vasculature and col-
lagen structures, the redox ratio based on endogenous NADH/
(FAD + NADH) had been imaged by intravital microscopy with 
multiphoton fluorescence lifetime microscopy (FLIM), and redox 
ratio changes have been found to relate to changes observed by 
18F-FDG PET, and, in ovarian cancer, were related to disease risk 
(49). As fluorescence lifetime changes with binding state and TME 
of metabolic enzymes (49), multiphoton FLIM, combined with 
other imaging modalities and intravital microscopy, is uniquely 
qualified to observe such changes in vivo, with the limitation of 
imaging depth.
Tumor vascularization, lymph vasculature, and vascular 
response to treatment have also been evaluated by intravital 
microscopy within the context of tumor growth and collagen 
structures (Figure 5) (66, 68, 86). Alexander et al. (66) imaged 
the intra- and perilymphatic invasion of fluorescent fibrosarcoma 
cells, indicative of a potential route of metastatic dissemination via 
the lymph vasculature located at the tumor margin (Figure 5A). 
Using intrinsic contrast, Vakoc et al. (68) imaged the antivascular 
effect of an antiangiogenic agent inhibiting VEGFR-2 on the 
tumor vasculature in  vivo at the microscopic level, depicting 
lymph and blood vessels (Figure 5B). They found in response to 
VEGFR-2 blockade that intratumor vessel length and mean vessel 
diameter decreased, as tumor growth was delayed (68).
Nakasone et  al. (353, 354) showed by intravital microscopy 
with a microlensed spinning-disk confocal microscope (355) of 
tumors in MMTV-PyMT mice expressing ACTB-ECFP in all 
host cells and c-fms-EGFP in myeloid cells, respectively, that 
vascular permeability and innate immune cell infiltration impact 
response to doxorubicin. The accumulation of macrophages with 
tumor growth as well as increased macrophage infiltration with 
increased metastatic ability have been imaged non-invasively 
in breast cancer models by fluorescence-reflectance imaging 
using a fluorescently labeled specific probe for alarmin S100A9, 
a calcium-binding protein secreted by monocytes/macrophages 
with the protein complex S100A8/A9 acting as mediator between 
tumor and immune cells (69) (Figure 6).
The fairly recent development of MRI/PET instrumentation 
permits the simultaneous imaging of metabolic, anatomical, and 
dynamic information, including cell tracking using appropriate 
labeled probes, during tumor progression and in response to 
treatment (70, 356–358) (Figure  7). The ability to effectively 
observe intratumoral function and heterogeneity over time by 
simultaneous MRI/PET has been demonstrated in a carcinoem-
bryonic antigen-expressing colorectal adenocarcinoma model 
(Figure 7) (70). A recent study showed that microvessel volume 
and density index (determined from MRI) were significantly 
lower for glioblastoma tumors treated with bevacicumab and the 
PI3K/mTOR inhibitor BEZ235 combined than for tumors treated 
with bevacicumab alone, while 18F-FET (O-(2-[18F]Fluoroethyl)-
l-tyrosine) uptake, a PET tracer to assess vessel amino acid 
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transport, remained unchanged between the two treatments 
(359). Further, tumor growth, as determined from MRI, and cell 
proliferation, as determined from 18F-FLT PET, were the same 
for the bevacicumab/BEZ235 combination therapy and the bev-
acicumab alone treatment groups (359). The in vivo results were 
validated by ex vivo studies (359).
While still significant more research needs to be done, these 
studies show the potential of harnessing the strengths of different 
imaging modalities to image tumor–stroma interaction within 
the TME in vivo, and thus, enhancing our understanding of its 
impact on tumor growth and treatment response.
CONCLUSiON
The strengths of optical imaging are its high sensitivity for CAs, 
ability to use a wide range of probes, including activatable probes 
and reporter genes, and compared to other imaging modalities, 
such as MRI and PET, low cost. However, optical imaging is 
typically semiquantitative, limited by penetration depth, small 
field of view, and, depending on method, high background 
signals and lack of tomographic information. Some of these 
limitations are overcome by PAI, which permits real-time 
quantitative imaging but is hampered by the range of available 
CAs. Ultrasound imaging is a low cost, rapid, real-time imaging 
modality with high temporal and spatial resolution, but has a 
limited field of view with low soft tissue contrast, and is typically 
semiquantitative and user dependent. Computer tomography 
is rapid, permits whole-body imaging, has high spatial resolu-
tion, is user independent, and mostly low cost, but is limited 
by its low sensitivity to CAs, lack of endogenous soft tissue 
contrast and exposure to radiation. Scanners for MRI (MRSI), 
PET, and SPECT are high in cost with the distinct advantage of 
whole-body imaging capabilities. While MRI has excellent soft 
tissue contrast, high spatial resolution, and has a wide range of 
methods available for tissue imaging and vessel characterization, 
it is limited by its low sensitivity and the fairly long acquisitions, 
the latter particularly prominent in spectroscopic imaging. To 
overcome these challenges, new methods, such as hyperpolar-
ized 13C MRSI, are being actively developed. The high sensitivity 
of PET and SPECT, respectively, is offset by their low resolution 
(1–2  mm), lack of morphological information and radiation 
exposure from the radioactive tracers, whose half-lives range 
from 75 s (Rb-82) to 4.18 days (I-124) for PET radioisotopes and 
from 6 h (Tc-99m) to 59 days (I-125) for SPECT tracers. With the 
advancement of MRI/PET, the power of various MRS and MRI 
methods beyond anatomy and DCE-MRI, such as MRS(I), can 
be harnessed for future studies, distinguishing itself from PET/
CT with reduced radiation exposure, the latter making MRI/
PET a powerful tool for serial monitoring.
While CT, MRI (MRSI), PET, SPECT, and US are already 
standard imaging tools in the clinic, for localized applications, 
e.g., detecting cancer cells at tumor margins during surgery 
(360), optical imaging is being assiduously developed. Aside from 
physical parameters specific to each imaging modality, clinical 
imaging of tumor–stroma interaction will also be in part defined 
by the successful development of safe tracers/CAs.
In the majority of preclinical studies, specific aspects of 
the TME and its stromal components have been investigated 
separately (a few aspects at a time), selecting the non-invasive 
preclinical imaging modality best suited for the task. However, 
recent strong evidence pointing to the importance of the interac-
tion between tumor cells and multiple components of the TME in 
tumor development, growth, metastases, and treatment response, 
including drug resistance, has generated a strong interest to fur-
ther develop imaging technologies to investigate tumor–stroma 
interactions non-invasively in vivo. Despite recent research efforts, 
the comprehensive characterization (including serial monitor-
ing) of the TME and tumor–stroma interactions non-invasively 
in vivo requires further advancement and to take advantage of the 
strengths of multimodal imaging tools for preclinical studies, and 
ultimately for clinical translation.
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